About 15% of patients with diabetes develop a Diabetic foot ulcer (DFU). It is an open sore or wound commonly located on the bottom of the foot.ANGIPARS™ is an Iranian-produced herbal remedy based on the extract of Melilotus officinalis. The aim of this study was More
About 15% of patients with diabetes develop a Diabetic foot ulcer (DFU). It is an open sore or wound commonly located on the bottom of the foot.ANGIPARS™ is an Iranian-produced herbal remedy based on the extract of Melilotus officinalis. The aim of this study was to make a systematic review focused on determination of the effect of ANGIPARS™ on wound healing in patients with diabetes. The study was conducted in accordance with the PRISMA guidelines. Articles included in the review cover the period from the discovery of ANGIPARS™ to August 18, 2018. The data were analyzed using a descriptive method of Excel 2007 Software.Five articles with total number of 171 patients were included in the systematic review (SR) phase. In three articles, the methods were based on mm2 units and in the two others on cm2 units. Patients' follow-up varied from 4 weeks to 6 months after the intervention. In all patients, ANGIPARS™ responds well to the DFU disease. Due to the positive effect of the herbal drug, it is recommended to administer it for wound healing in patients with diabetes.
Manuscript profile
